SPC365

Unveiling the Population Dynamics of Sepsis Cardiomyopathy: A Comprehensive Evaluation

Session: SESSÃO DE POSTERS 33 - DOENÇAS CARDIOVASCULARES - MINOCA E SÍNDROME DE TAKOTSUBO
Speaker: Inês Caldeira Araújo

Congress: CPC 2025
Topic: E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme: 14. Acute Cardiac Care
Subtheme: 14.3 Acute Cardiac Care – CCU, Intensive, and Critical Cardiovascular Care
Session Type: Cartazes
FP Number: ---
Authors: Inês Caldeira Araújo; Ana Abrantes; Catarina Gregório; Miguel Azaredo Raposo; João Fonseca; Marta Vilela; Daniel Cazeiro; Diogo Ferreira; João Cravo; Sofia Esteves; F. J. Pinto; Doroteia Silva

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Introduction: </strong></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Sepsis&nbsp;cardiomyopathy (SC) is a condition marked by ventricular dilation, reduced ejection fraction (EF) and normal filling pressures, typically resolving within 7&ndash;10 days in septic patients. Despite its clinical importance, SC is poorly understood, with limited research and an unclear prognosis.</span></span></span></p>

<p>&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Purpose:</strong></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"> This study aims to characterize patients diagnosed with SC between 2022 and 2023 and compare their clinical profiles and Intensive Care Unit (ICU) outcomes with those of patients without SC (noSC).</span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">&nbsp;</span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Methods: </strong></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Retrospective, observational, single-center study of consecutive patients with SC diagnosis, between January 2022 and December 2023.&nbsp;</span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">&nbsp;</span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Results: </strong></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">306 patients were included, 19% with SC and 81%&nbsp; without SC. Cardiovascular comorbidities and previous structural heart disease were comparable between groups (SC: 20.4% vs. noSC: 22.2%). Median ICU length of stay did not differ significantly between the two groups (SC: 4 vs. noSC: 5 days). However, in-hospital cardiac arrest occurred more frequently in SC patients (20.7% vs. 8.1%; p=0.005). ICU mortality was significantly higher in the SC group (55.2% vs. 39.3%; p=0.027), although overall in-hospital mortality showed no significant difference (SC: 56.9% vs. noSC: 52%). Infection source control and time to effective source control were similar between the two groups. Regarding end-organ dysfunction, SC patients exhibited higher rates of encephalopathy (56% vs. 36.6%; p=0.014), hepatocellular injury (78% vs. 57.7%; p=0.009), and renal dysfunction (6.9% vs. 9.9%; p=0.017). Analogously, inotrope and vasopressor use was higher in SC patients, being noradrenaline and dobutamine the most used drugs (peak noradrenaline dose 165 mcg/min in SC vs 80 mcg/min, peak dobutamine 5 mcg/Kg/min in both groups). Mean SvO2 at admission was significantly lower in SC patients (63.3% vs. 69.6%; p=0.010), while peak lactate levels were significantly higher (SC: 64 mg/dL vs. noSC: 46 mg/dL; p=0.011). Patients in both groups had similar CRP peak (26.1 mg/dL in both groups), but SC patients had higher peak troponin T (SC: 62 ng/L vs. noSC: 49 ng/L, p value 0.070) and NTproBNP levels (SC: 15434 pg/mL vs noSC: 4887 pg/mL, p value 0.004).&nbsp;</span></span></span></p>

<p style="text-align:justify"><br />
<span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Conclusions: </strong></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">SC worsens septic patient outcomes by impairing hemodynamic stability and organ dysfunction, emphasizing the need for early detection and treatment.</span></span></span></p>

<p>&nbsp;</p>